Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Wang

Neurology Memphis, TN Medical Doctor

NPI 1619945532 CMS profile 163873

5100 Sanderlin Ave Ste 2100, Memphis, TN 38117

Open in the dashboard

General payments

$27,114

561 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Wang of Memphis, TN is reported in the CMS Open Payments database as having received $27,114 across 561 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,384 92
2024 General $1,648 85
2023 General $2,799 72
2022 General $1,296 65
2021 General $1,686 102
2020 General $1,216 83
2019 General $1,086 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Wang
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to James Wang were reported at $17,384. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year James Wang Neurology median Middle half National median
2019 $1,086 $474 $118–$2,177 $163
2020 $1,216 $367 $82–$2,309 $114
2021 $1,686 $438 $104–$2,547 $132
2022 $1,296 $442 $103–$2,388 $149
2023 $2,799 $464 $119–$2,312 $160
2024 $1,648 $468 $119–$2,323 $164
2025 $17,384 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $6,354 18 payments
  2. Pfizer Inc. $5,462 35 payments
  3. Argenx US, Inc. $4,737 23 payments
  4. Amneal Pharmaceuticals LLC $1,630 17 payments
  5. Novartis Pharmaceuticals Corporation $1,028 54 payments
  6. Alexion Pharmaceuticals, Inc. $913 33 payments
  7. UCB, Inc. $892 39 payments
  8. AbbVie, Inc. $644 48 payments
  9. Horizon Therapeutics plc $553 24 payments
  10. Allergan Inc. $485 38 payments
  11. Other $4,416 232 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $15,548 7 payments
  2. Food and Beverage $10,272 543 payments
  3. Travel and Lodging $1,039 5 payments
  4. Education $215 4 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41 2 payments
Products named General payments · program years 2019–2025
  1. UPLIZNA Inflammation/Rare Disease $6,319 16 payments
  2. PANZYGA $5,077 6 payments
  3. VYVGART Hytrulo $4,558 18 payments
  4. KESIMPTA $569 26 payments
  5. UPLIZNA Uplizna $553 24 payments
  6. BOTOX $461 34 payments
  7. ULTOMIRIS $424 17 payments
  8. NURTEC ODT $386 29 payments
  9. UBRELVY $333 32 payments
  10. VYVGART $254 8 payments
  11. Other $6,488 367 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,978

Median for Neurology: 833

Drug cost

$200,896

Median for Neurology: $202,670

Branded share of claims

8.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Copaxone Glatiramer Acetate Brand 21 $122,150
Rytary Carbidopa/Levodopa Brand 29 $19,142
Gabapentin Generic 625 $7,310
Levetiracetam Generic 193 $5,590
Carbamazepine Generic 93 $4,734
Pyridostigmine Bromide Generic 29 $4,485
Divalproex Sodium Generic 138 $4,451
Topiramate Generic 219 $3,304
Amantadine Amantadine Hcl Brand 50 $3,288
Donepezil Hcl Generic 304 $3,092

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$4,509,615

Of which drugs: $4,216,056

Medicare patients

681

Average age 74

Services billed

88,382

365 women, 316 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 49%
Ischemic heart disease 49%
Chronic kidney disease 40%
Heart failure 33%
Depression 33%
Atrial fibrillation 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg J1576 Office 34 41,520 $2,198,185
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 18 10,130 $347,846
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 11 1,848 $425
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 37 473 $303

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $195
$195 — —
Rystiggo
  • UCB, Inc. $148
$148 — —
NURTEC ODT
  • PFIZER INC. $145
$145 — —
Nayzilam
  • UCB, Inc. $141
$141 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $132
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

561 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record